Heart Failure: DR Kaem Shir Ali
Heart Failure: DR Kaem Shir Ali
Heart Failure: DR Kaem Shir Ali
Main causes:
Ischaemic heart disease (35–40%)
Cardiomyopathy (dilated) (30–34%)
Hypertension (15–20%)
Other causes:
Cardiomyopathy (undilated): hypertrophic, restrictive
(amyloidosis, sarcoidosis)
Valvular heart disease (mitral, aortic, tricuspid)
Congenital heart disease (ASD, VSD)
Alcohol and drugs (chemotherapy – trastuzumab, imatinib)
Hyperdynamic circulation (anaemia, thyrotoxicosis,
haemochromatosis, Paget’s disease)
Right heart failure (RV infarct, pulmonary
hypertension, pulmonary embolism, (COPD))
Tricuspid incompetence
Arrhythmias (atrial fibrillation, complete heart block,
the sick sinus syndrome)
Pericardial disease (constrictive pericarditis,
pericardial effusion)
Infections (Chagas’ disease), e.g. myocarditis
Factors aggravating heart failure
• High output HF: cardiac output > 3.5 L/min per m² or upper
limit of normal (before development of HF). Seen in
thyrotoxicosis, pregnancy , anemia , Paget's disease , beriberi
and ateriovenous fistulas ,with underlying heart disease .
Forward Failure : inadequate cardiac output that
leads to diminished perfusion of vital organs
leading to ischemia , brain mental confusion
,skeletal muscles weakness , kidneys sodium and
water retention.
Pericardial disease .
Liver disease.
Nephrotic syndrome
Protein losing enteropathy.
Investigations
• ECG
• Chest X-ray.
- cardiomegaly
- pleural effusion
- Bat’s wings appearance.
- Pneumonia
• Echo
• Cardiac biomarker
• RF test
• CBC
• Blood sugar
• Lipid profile.
• Serum Electrolyte
• B-type natriuretic peptide (BNP) > 400 pg/ml
• Thyroid function test
X-Ray in Left ventricular failure
Management
• Monitor fluid balance, daily weight (aim to lose 0.5–1 kg
daily), and daily urea and electrolytes.
• No-added-salt diet.
• Diuretics
• Angiotensin-converting enzyme (ACE) inhibitor,angiotensin II
receptor blocker can be used if ACE inhibitor not tolerated.
• Beta-blocker, eg bisoprolol, carvedilol or nebivolol, in patients
with stable NYHA II–IV symptoms. Only start when clinically
stable and euvolaemic.
• Spironolactone in patients with NYHA III–IV.
• Consider anticoagulation (AF and LV thrombus).
Complications
• AF.
• Ventricular tachycardia.
.
• Sudden death.
• Progressive heart failure.
• Renal impairment
Goals of treatment
• To improve symptoms and quality of life.
• To decrease likelihood of disease progression.
• To reduce the risk of death and need for
hospitalization
Thank you
Questions!!!!
End